1. Bast RC, Klug TL, John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:887–90.
2. Gynecologic Oncology Branch of the Chinese Medical Association. The standard diagnosis and treatment of recurrent ovarian cancer (recommended). Chin J Obstet Gynecol. 2003;38:717–9.
3. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.
4. Zeng J, Yin J, Song X, et al. Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma. J Cancer. 2016;7:2327–32.
5. James L, Edward P, John M, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2013;89:233–8.